China NMPA Drug Inspection - Daqing Yuanwang Hospital - Tinea Capsules

The Heilongjiang Provincial Food and Drug Administration issued an announcement on May 4, 2018, revealing significant compliance failures identified through sampling inspections. Six testing institutions found 18 batches of drugs, preparations, and traditional Chinese medicine decoction pieces to be substandard. These products originated from 13 manufacturers, including Jilin Mizhikang Pharmaceutical Co., Ltd., Shanghai Pujin Linzhou Pharmaceutical Co., Ltd., and Hebei Zhijia Pharmaceutical Co., Ltd. Main violations encompassed failures in inspection parameters, content determination, product properties, identification tests, and extractives. In response, regulatory bodies implemented immediate control measures, such as sealing and seizing affected batches and suspending their sale and use. Operating under Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*, the Provincial Bureau mandated local food and drug administrations to investigate these illegal acts. They are required to publicly disclose investigation results and imposed penalties on the involved enterprises within three months, and subsequently report findings to the Provincial Bureau. This action highlights a firm commitment to upholding drug quality and public health standards.